News
3d
Investor's Business Daily on MSNSarepta Catapults 20% On Restructuring Plans In The Wake Of Two Patient DeathsSarepta stock catapulted Thursday after the company announced a restructuring that includes 500 layoffs in the wake of two ...
Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the ...
3d
Zacks Investment Research on MSNSRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline PivotsShares of Sarepta Therapeutics SRPT surged more than 30% in after-market trading yesterday after the company announced a ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...
The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...
3d
GlobalData on MSNSarepta Therapeutics to cut 500 jobs amid restructuringThe company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...
Massachusetts-based Sarepta Therapeutics, facing scrutiny from regulators, is reducing its global workforce by 36% in an ...
Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...
Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The ...
The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results